These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12678250)

  • 21. Alternatives and developing countries.
    Milstien JB; Dellepiane N
    Dev Biol Stand; 1999; 101():203-8. PubMed ID: 10566794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene-expression-based quality scores indicate optimal harvest point in Bordetella pertussis cultivation for vaccine production.
    van de Waterbeemd B; Streefland M; Pennings J; van der Pol L; Beuvery C; Tramper J; Martens D
    Biotechnol Bioeng; 2009 Aug; 103(5):900-8. PubMed ID: 19405154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CBER: new approaches to biological product testing.
    Donlon JA
    Dev Biol Stand; 1999; 101():21-5. PubMed ID: 10566770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N-glycan charge assay--an alternative for potency assays of therapeutic glycoproteins?
    Hermentin P; Witzel R; Schwick-Wagner P; Blumrich M
    Dev Biol (Basel); 2002; 111():89-97. PubMed ID: 12678228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potency assays for therapeutic live whole cell cancer vaccines.
    Petricciani J; Egan W; Vicari G; Furesz J; Schild G
    Biologicals; 2007 Apr; 35(2):107-13. PubMed ID: 16882459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential application of the consistency approach for vaccine potency testing.
    Arciniega J; Sirota LA
    Dev Biol (Basel); 2012; 134():135-9. PubMed ID: 22888606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conversion of a CHO cell culture process from perfusion to fed-batch technology without altering product quality.
    Meuwly F; Weber U; Ziegler T; Gervais A; Mastrangeli R; Crisci C; Rossi M; Bernard A; von Stockar U; Kadouri A
    J Biotechnol; 2006 May; 123(1):106-16. PubMed ID: 16324762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The validation of potency tests: hurdles identified by EMA/CVMP/IWP.
    Woodland R
    Dev Biol (Basel); 2012; 134():69-73. PubMed ID: 22888597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a critical process parameter: oxygen limitation during cultivation has a fully reversible effect on gene expression of Bordetella pertussis.
    Streefland M; van de Waterbeemd B; Kint J; van der Pol LA; Beuvery EC; Tramper J; Martens DE
    Biotechnol Bioeng; 2009 Jan; 102(1):161-7. PubMed ID: 18683249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The target animal safety test--is it still relevant?
    Advisory Group on Alternatives to Animal Testing in Immunobiologicals
    Biologicals; 2002 Dec; 30(4):277-87. PubMed ID: 12474863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternatives to animal experimentation: the regulatory background.
    Garthoff B
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):388-92. PubMed ID: 15982684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Constant specific growth rate in fed-batch cultivation of Bordetella pertussis using adaptive control.
    Soons ZI; Voogt JA; van Straten G; van Boxtel AJ
    J Biotechnol; 2006 Sep; 125(2):252-68. PubMed ID: 16621094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduction in animal use in the production and testing of biologicals.
    Festing MF
    Dev Biol Stand; 1999; 101():195-200. PubMed ID: 10566793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro potency testing of inactivated biologics: current situation in the E.E.C.
    Soulebot JP; Milward F; Prevost P
    Vet Microbiol; 1993 Nov; 37(3-4):241-51. PubMed ID: 8116185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meeting the regulatory requirements for pharmaceutical production of recombinant DNA derived products.
    Werner RG; Langlouis-Gau H
    Arzneimittelforschung; 1989 Jan; 39(1):108-11. PubMed ID: 2719737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fed-batch cultivation of Bordetella pertussis: metabolism and Pertussis Toxin production.
    Thalen M; Venema M; Dekker A; Berwald L; van den IJssel J; Zomer B; Beuvery C; Martens D; Tramper J
    Biologicals; 2006 Dec; 34(4):289-97. PubMed ID: 16500113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microarray-based gene expression analysis as a process characterization tool to establish comparability of complex biological products: scale-up of a whole-cell immunotherapy product.
    Wang M; Senger RS; Paredes C; Banik GG; Lin A; Papoutsakis ET
    Biotechnol Bioeng; 2009 Nov; 104(4):796-808. PubMed ID: 19591186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ensuring the consistency of rDNA-derived biologicals: the contribution of gene sequencing.
    Griffiths E
    Dev Biol Stand; 1994; 83():179-82. PubMed ID: 7883093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ensuring quality of in vitro alternative test methods: issues and answers.
    Gupta K; Rispin A; Stitzel K; Coecke S; Harbell J
    Regul Toxicol Pharmacol; 2005 Dec; 43(3):219-24. PubMed ID: 16099570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.